KEW Group Inc. (KEW) provides multiple services to oncologists to assist in treatment decisions for cancer patients. KEW provides genomic testing for patient tumor samples (KEW MDx) and genomic information important to diagnostic and treatment decisions that assist physicians and are detailed in cancer-specific Therapeutic Pathways (KEW TPx). KEW MDx's CancerPlexSM test is the first of the company's diagnostic services designed to assist community oncologists in providing state-of-the-art genomic testing that previously had been available only at large cancer treatment and academic centers. KEW is currently working with seven oncology practices in six different states to refine Therapeutic Pathways for seven types of cancer (breast, colorectal, lung, melanoma, lymphoma, thyroid and pancreatic). These seven practices all participate in a Center for Medicare and Medicaid Innovation Grant, which is developing and testing a Community Oncology Medical Home model, known as COME HOME. The grant is administered through Innovative Oncology Business Solutions, Inc., the organization that oversees and manages COME HOME. KEW's Treatment Pathways integrate newly emerging cancer genomic information that follows evidence standards essential to how and when to perform molecular tests, as well as inform care decisions.